{"id":811124,"date":"2025-02-10T16:09:13","date_gmt":"2025-02-10T21:09:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/"},"modified":"2025-02-10T16:09:13","modified_gmt":"2025-02-10T21:09:13","slug":"ibio-reports-fiscal-second-quarter-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/","title":{"rendered":"iBio Reports Fiscal Second Quarter 2025 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Feb.  10, 2025  (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress.<\/p>\n<p align=\"justify\">\u201cIn our second fiscal quarter we further strengthened our leadership with key Board appointments, reinforcing our commitment to innovation and execution as we work to develop next-generation therapeutics,\u201d said CEO and Chief Scientific Officer Dr. Martin Brenner, Ph.D. \u201cFollowing more recent developments, we also want to highlight the significant strides we have made in advancing our preclinical pipeline with the in-licensing of potentially best-in-class IBIO-600, the notable discovery of a novel Activin E antibody, and the launch of a bispecific antibody program targeting myostatin\/activin A. We are excited by the momentum we have built through these results and remain focused on leveraging our AI-driven platform as we aim to transform the treatment landscape for patients with cardiometabolic diseases and obesity, offering hope for more effective, targeted therapies addressing the underlying causes of these conditions while improving overall metabolic health and quality of life.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Fiscal Second Quarter 2025 &amp; Recent Corporate Updates: <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Discovered a <a href=\"https:\/\/ir.ibioinc.com\/news-events\/press-releases\/detail\/231\/ibio-discovers-novel-antibody-targeting-activin-e-in\" rel=\"nofollow\" target=\"_blank\">novel antibody targeting activin E in collaboration with AstralBio<\/a>, leveraging iBio\u2019s Machine-Learning Antibody Engine to overcome significant technical challenges, demonstrating the platform\u2019s ability to engineer innovative therapeutics potentially for cardiometabolic disease and obesity.\n<\/li>\n<li style=\"text-align:justify\">Expanded iBio\u2019s cardiometabolic and obesity program with <a href=\"https:\/\/ir.ibioinc.com\/news-events\/press-releases\/detail\/230\/ibio-expands-cardiometabolic-and-obesity-program-with\" rel=\"nofollow\" target=\"_blank\">IBIO-600<\/a>, the long-acting anti-myostatin antibody in-licensed from AstralBio in January. IBIO-600 was discovered by AstralBio through the use of iBio\u2019s Machine-Learning Antibody Engine and was designed for subcutaneous administration with the potential for an extended half-life.\n<\/li>\n<li style=\"text-align:justify\">Initiated a <a href=\"https:\/\/ir.ibioinc.com\/news-events\/press-releases\/detail\/230\/ibio-expands-cardiometabolic-and-obesity-program-with\" rel=\"nofollow\" target=\"_blank\">bispecific antibody program<\/a> targeting myostatin\/activin A to promote weight loss, muscle preservation, and prevent weight regain with plans for clinical investigation in obesity and cardiometabolic disorders in 2026. The program leverages iBio\u2019s Machine-Learning Antibody Engine as well as the technology of IBIO-600.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <a href=\"https:\/\/ir.ibioinc.com\/news-events\/press-releases\/detail\/229\/ibio-strengthens-board-with-appointment-of-two-new\" rel=\"nofollow\" target=\"_blank\"><br \/>\n            <u>Strengthened the Board of Directors<\/u><br \/>\n          <\/a> with the appointments of biotech industry veterans David Arkowitz and Ant\u00f3nio Parada on November 25, 2024.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">In January we further extended our cash runway with the <a href=\"https:\/\/ir.ibioinc.com\/news-events\/press-releases\/detail\/232\/ibio-announces-new-investments-from-board-members-and\" rel=\"nofollow\" target=\"_blank\">closing of a private placement offering<\/a> with members of our Board of Directors and Officers, underscoring their confidence and support in our strategy to advance as a clinical-stage biotech.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Fiscal Second Quarter 2025 Financial Results:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Revenue of $0.2 million was reported for services provided to a collaborative partner during the quarter ended Dec. 31, 2024.\n<\/li>\n<li style=\"text-align:justify\">R&amp;D and G&amp;A expenses for the second quarter of fiscal 2025 totaled approximately $4.6 million as compared to $4.5 million in the same period of fiscal year 2024, an increase of approximately 3%. This slight increase is a result of additional spending on consumables supplies and research related activities offset by lower G&amp;A personnel related costs, consulting fees and outside services spending. Net loss from continuing operations for the second quarter ended Dec. 31, 2024, was approximately $4.4 million, or $0.48 per share, compared to a net loss of approximately $4.5 million, or $2.42 per share, in the same period of fiscal 2024.\n<\/li>\n<li style=\"text-align:justify\">Cash, cash equivalents and restricted cash as of Dec. 31, 2024, was approximately $7.2 million, inclusive of $0.2 million of restricted cash.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About iBio, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">iBio\u00a0(NYSEA: <strong>IBIO<\/strong>) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.\u00a0 For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qKBDYgHCK6C2XA5Jj2W1Uln6CbyaW012FMsn3NoqBrKyR5K8kTjeKDt-6US3-kOD-8lqb68sL2jKz4nCCz9PNg==\" rel=\"nofollow\" target=\"_blank\">www.ibioinc.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jmq8aBrFkXlpOhGooqSpWqXRgapAs39rb8EwEC8YxhOutmr2vyvOxrjkTM6R0G7MFK3PvbW8ray6jzo56fh-ugRUgN2Y9gGmrBZOG77E78XbwxZF6NjtUv5au06KyzoRp1943d590x4SiAsZDwsk2NC5nil3evyqA2f7Z-clns8-vK0EPFrvzgiXPkHf-g-3-Ay2C2imWLnlQ-Y_IS-dPU4Z3_FbdL3v8TB4TwNV6EZ-MjlzTG5MVHch885P-njI7ghzPjo7QqSxUKWXyjeSkA==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>. <\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor Statement<\/strong>\n      <\/p>\n<p align=\"justify\">Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements.\u201d The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the potential for IBIO-600 to be best-in-class; leveraging iBio\u2019s AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity, offering hope for more effective, targeted therapies addressing the underlying causes of these conditions while improving overall metabolic health and quality of life; IBIO-600\u2019s potential for an extended half-life; iBio\u2019s clinical investigation in obesity and cardiometabolic disorders in 2026; advancing as a clinical-stage biotech; the creation of a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and transforming drug discovery, accelerating development timelines, and unlocking new possibilities in precision medicine&#8230; Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including iBio\u2019s ability to -leverage its AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity with more effective, targeted therapies addressing the underlying causes of these conditions while improving overall metabolic health and quality of life; extend the half-life of IBIO-600; advance as a clinical-stage biotech and commence a clinical investigation in obesity and cardiometabolic disorders in 2026; create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine the ability to advance iBio\u2019s internal pipeline priorities in immuno-oncology and cardiometabolics, and drive partnerships in new therapeutic areas, the ability to finance when needed and the risk factors described in the Company\u2019s Annual Report on Form 10-K for the year ended Juen 30, 2024, and the Company\u2019s subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong>\n      <\/p>\n<p>iBio, Inc.<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R_ySscs6OJWXmU8p3N1BgV5ZxearxTv0_Up-HPWxgiFfYGN8gP7odYY83D6wKdyeSwD6cC-l-rh9tblbmzQ9p2438W5a6iuuzXrv2IfYt10QnkNBJPs9FD8F7-dEFAGVVR1igQ-6IBnqyp7xRjpulDgQdcOSRoa05Sooj8b2fc4lUAJaIUIQ5fTTWsWXBQOflYH5SVDeexD-4pdITvlGpfJCD_RNSGirMp1Nex7CTPb7oSEXYTqCorhT4Zy7c7n2yLRNajcdHeamHx1ULYQVN15jWW3fxUhlfMh9Vw6_Vq9HA_G2dXiPss1RmMDfC3QXFvOvXlMkm8Yi_Tfa9axWHHTySkmzV9qf16sIOlAi0ZXYj633zB-LUgYbyg6lCdab7ME5ca0YKGUqdjlmY_nZNl2V-Qjnl-DAY173ie9zu33x1HSCcINU4pkOKc0F0QQOCRIKK47Bzduho8iPcQX5PFoEAN-wUFMpR1APMefemNNi_pPuD0HS1PWnj-VY3X7E6SBUWLZVU9HiDmViXrufBEqSGzFDrVkEj-PW_DPQmEHimoS3VmSeJfT_KgtA8j_XDOJ3pQmprbU6loXkEO7tWPKeZ1-lqHXPuMb6qb0HdSsJAm2IkqR24TuwKOwwGnXTiyydWkwx7BlZDbGnumjDjqr2gHnsgfO-Nv4M7rzWxUJd9rV9jXHJekit4p5kWExuKzvsIunSgcS5hjQ3XnvG7GcaZ8m68blTPZhCE0ONGMi_b7lynh7KkUl1CJlYBFZDOCzczn2WQUk3CNrwJhV6Gi6VAT1LNFZotFqrCqac5Oj_9KK4nX59GAPghYReFPbBtzLJzGJejomgE2V_3erM2rlYHggKH3YaZvDO3sZvznE4cYisvLLIwFSPlt3g6WntCXPOgqe_qJE9_uBNGe1Vdvs4zrimwE7Qr_SS5mmTn_QFDMV5U30tm22RAzBIhxJCQqQL3oIvgV-3DdHZnUkwIOzuvS1cSXYpM_2RyYidji5cKMyf62ZkJcT7AkrqYTMN\" rel=\"nofollow\" target=\"_blank\">ir@ibioinc.com<\/a><\/p>\n<p>\n        <strong>Media Contacts:<\/strong>\n      <\/p>\n<p>Ignacio Guerrero-Ros, Ph.D., or David Schull<br \/>Russo Partners, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TMZ5njGxft0yDVlpO5kE-A0767h9SZ-xNQqUeKOXumzbGUK-AsgJk_bj646-DUQZ82uUeeRB3sqMgotD4nm-2lCYXETpkIthEzLXGCZgYMOO7_OXOk6Ohj9XlmsQ0iwUbkrk2zTDqPqNiY8Wk25aRwh3Ev9sXhW22F-CS5YSHgLs4tRrqOGHmtcUjgoUmOflsXNN9b4Svkha3pVwSowYOJAdkMAKXlE0vz-xYgkPK2_AyAaYT1-3VrfCsK0d4iZrBLbiHT26WCT6HgfEG5DWYXquQGiZpWZAYN4TTvUiX0l5DSoQ4NO86lFCMtMvzft2NY7p64WhqElDjXZSpMl-4vlrxCJ0WjTXo8qGvNls6Qn_m7Z6uP2i4cfCF00Lw1pG\" rel=\"nofollow\" target=\"_blank\">Ignacio.guerrero-ros@russopartnersllc.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jztVJdFRPDurGshnE5SoEqMZwK_V8lSIFYoXk5sUdYPqKZ8Gt4SeRFS7j3Zj3VFu7_fjXrNuE1zkTz5-Rr2ROjDPxK9vwf2v0X_KaynZ_KWJh4RSI4aObMgVHIOiQyoDbSUoPU_i8b87AEtFDI--cBq2WeGZR8C9s_Z3K6WrT9At0rwbGAgbSpKU6Gbj7r60GBXJCWVi9gjhrST5G4n9i4ou-c_h2_64CMdVX4Cu3CWSTBkud2dNUfA-U_qyqGUIYg74u_XePt3CCZ6nA3X3BAZzbvIPq-qgRHA15v-vf4GTu39XI3pNr6c_rp1p9na3\" rel=\"nofollow\" target=\"_blank\"><br \/><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xLjSJgWtWGQ-STOt_DV56eeiED_0K5DLIOllK__xkC4lR9t0-WElhi7kbROppWxr4p-Sm61Cq3hejgsykEWjvubgtEpq6hLrfQrn_VEpR5Gz2QnsCUkVVblPEB27RB0sXme1TLNzMJC5xru3bMwRa7tD1V4XhkSZ21Qfu4jmRMZClohKZuU9pNq-cgmanIDBa3HThhf6i_kEXkUJ1rZMkEQGgGjGIMMAgmmBthxKpiNNr1a9GooLexNueY_zmLAvQcZoHks3S_4dlKgEz-oAHO4mLJlG6_4Sxn0fjZnq8QaHJR2T2cCRgiFEGgTnOYmaP3Le9CkobI1zFzdYAZul1g==\" rel=\"nofollow\" target=\"_blank\">David.schull@russopartnersllc.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O2aEg-NY4NS1cyP01e83ggxw0jWJwnNLn_c25czjOFy1og4dn9DR1lPInf4OMe6Qj_KtPTfSdPwG2iL9vdOKLbRV9AirnkbwpMuE3r-6GwY5keaH6ye9OmY67YLK_WmiNBFtb8KB1vdfNMjCz8XU9_cbJ6IR8viPtinFKA3oBqoyPtHf6nJGrZQg9FRvzPblwRYwUYl2ykzGmHwMrTJ5wPT3Hk65z8sppyz_gwuDoaZ3QQJaja1MtaH3WPXo-T4Ho0-qhSHJdj3eiAs7l4COqUepIbJ5lwH4O2MnucHLwnY=\" rel=\"nofollow\" target=\"_blank\"><br \/><\/a>(858) 717-2310 or (646) 942-5604<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDI3MGE4Y2EtNjM0Zi00ZmMwLTkzY2ItNGRlMjg1M2UzMTI4LTEwOTkxNDQ=\/tiny\/iBio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. \u201cIn our second fiscal quarter we further strengthened our leadership with key Board appointments, reinforcing our commitment to innovation and execution as we work to develop next-generation therapeutics,\u201d said CEO and Chief Scientific Officer Dr. Martin Brenner, Ph.D. \u201cFollowing more recent developments, we also want to highlight the significant strides we have made in advancing our preclinical pipeline with the in-licensing of potentially best-in-class IBIO-600, the notable discovery of a novel Activin E antibody, and the launch of a bispecific antibody program targeting myostatin\/activin A. We are excited by &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;iBio Reports Fiscal Second Quarter 2025 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-811124","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>iBio Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iBio Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. \u201cIn our second fiscal quarter we further strengthened our leadership with key Board appointments, reinforcing our commitment to innovation and execution as we work to develop next-generation therapeutics,\u201d said CEO and Chief Scientific Officer Dr. Martin Brenner, Ph.D. \u201cFollowing more recent developments, we also want to highlight the significant strides we have made in advancing our preclinical pipeline with the in-licensing of potentially best-in-class IBIO-600, the notable discovery of a novel Activin E antibody, and the launch of a bispecific antibody program targeting myostatin\/activin A. We are excited by &hellip; Continue reading &quot;iBio Reports Fiscal Second Quarter 2025 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-10T21:09:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iBio Reports Fiscal Second Quarter 2025 Financial Results\",\"datePublished\":\"2025-02-10T21:09:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/\"},\"wordCount\":1021,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/\",\"name\":\"iBio Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=\",\"datePublished\":\"2025-02-10T21:09:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-reports-fiscal-second-quarter-2025-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iBio Reports Fiscal Second Quarter 2025 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iBio Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"iBio Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk","og_description":"SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. \u201cIn our second fiscal quarter we further strengthened our leadership with key Board appointments, reinforcing our commitment to innovation and execution as we work to develop next-generation therapeutics,\u201d said CEO and Chief Scientific Officer Dr. Martin Brenner, Ph.D. \u201cFollowing more recent developments, we also want to highlight the significant strides we have made in advancing our preclinical pipeline with the in-licensing of potentially best-in-class IBIO-600, the notable discovery of a novel Activin E antibody, and the launch of a bispecific antibody program targeting myostatin\/activin A. We are excited by &hellip; Continue reading \"iBio Reports Fiscal Second Quarter 2025 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-10T21:09:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iBio Reports Fiscal Second Quarter 2025 Financial Results","datePublished":"2025-02-10T21:09:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/"},"wordCount":1021,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/","name":"iBio Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=","datePublished":"2025-02-10T21:09:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTcyNyM2NzQxODM1IzIwODc1NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-reports-fiscal-second-quarter-2025-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iBio Reports Fiscal Second Quarter 2025 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=811124"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811124\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=811124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=811124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=811124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}